MiMedx Group ^Company

MiMedx Group is a biopharmaceutical company, develops, and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. MiMedx Group’s proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications, OrthoFlo, an amniotic fluid-derived allograft for homologous applications, Physio, a bone grafting material comprising 100% bone tissue with no added carrier, and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. It also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue, AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process, and AmnioFill, a cellular tissue matrix allograft that enhances healing. MiMedX Group's products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. It sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group began operation on February 28, 2008. It has its headquarters in Marietta in Georgia.